ImpediMed CHIA:IPD Voorraadrapport Financiële gegevens bedrijf + 3 Analisten
ImpediMed Limited
CHIA:IPD Voorraadrapport
Marktkapitalisatie: AU$111.3m
IPD Overzicht aandelen ImpediMed Limited, een medisch technologiebedrijf, produceert en verkoopt medische apparatuur op basis van bioimpedantiespectroscopie (BIS)-technologie in de Verenigde Staten en Europa.
Beloningen Risicoanalyse Alle risicocontroles bekijken ImpediMed Limited Concurrenten Prijsgeschiedenis en prestaties
Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor ImpediMed Historische aandelenkoersen Huidige aandelenkoers AU$0.054 52 Week Hoogtepunt AU$0.16 52 Week Laag AU$0.043 Bèta 2.87 11 maand verandering -10.00% 3 maanden verandering -6.90% 1 Jaar Verandering -61.43% 33 jaar verandering -69.14% 5 jaar verandering -73.00% Verandering sinds IPO -70.81%
Recent nieuws en updates
ImpediMed Limited to Report Q1, 2025 Results on Oct 22, 2024 Oct 15
ImpediMed Limited, Annual General Meeting, Nov 19, 2024 Sep 27
Board Member recently bought AU$73k worth of stock Sep 03
Full year 2024 earnings released: EPS: AU$0 (vs AU$0.011 loss in FY 2023) Aug 30
Forecast to breakeven in 2027 Aug 29
ImpediMed Limited to Report Fiscal Year 2024 Results on Aug 29, 2024 Aug 23 Meer updates bekijken
ImpediMed Limited to Report Q1, 2025 Results on Oct 22, 2024 Oct 15
ImpediMed Limited, Annual General Meeting, Nov 19, 2024 Sep 27
Board Member recently bought AU$73k worth of stock Sep 03
Full year 2024 earnings released: EPS: AU$0 (vs AU$0.011 loss in FY 2023) Aug 30
Forecast to breakeven in 2027 Aug 29
ImpediMed Limited to Report Fiscal Year 2024 Results on Aug 29, 2024 Aug 23
Forecast to breakeven in 2026 Jul 30 ImpediMed Limited Appoints Parmjot Bains as CEO on an ongoing basis
ImpediMed Limited Appoints Fiona Bones as A Non-Executive Director Jun 08
New minor risk - Market cap size Jun 04
Independent Non-Executive Director recently bought AU$50k worth of stock May 15
ImpediMed Limited to Report Q3, 2024 Results on Apr 30, 2024 Apr 20
ImpediMed to Present Chronic Breast Cancer-Related Lymphedema Study Results at American Society of Breast Surgeons Annual Meeting Apr 11
Independent Non-Executive Director recently bought AU$100k worth of stock Mar 28
Independent Non-Executive Director recently bought AU$90k worth of stock Mar 02
No longer forecast to breakeven Feb 03
High number of new and inexperienced directors Feb 01
ImpediMed Limited to Report First Half, 2024 Results on Feb 27, 2024 Jan 23
Independent Non-Executive Director recently bought AU$135k worth of stock Dec 19 ImpediMed Limited Announces CFO Changes
ImpediMed Limited to Report Q1, 2024 Results on Oct 31, 2023 Oct 24
ImpediMed Limited, Annual General Meeting, Nov 30, 2023 Oct 12
High number of new directors Oct 05
ImpediMed Limited Announce the Appointment of Steven Chen as Chief Medical Officer Sep 27
Full year 2023 earnings released: AU$0.01 loss per share (vs AU$0.012 loss in FY 2022) Aug 31
ImpediMed Limited, Annual General Meeting, Sep 28, 2023 Aug 18
ImpediMed Limited to Report Q4, 2023 Results on Jul 24, 2023 Jul 17
ImpediMed Limited Appoints Daniel Sharp as Director Jul 06
Executive Director recently bought AU$144k worth of stock Jun 28
Independent Non-Executive Chairman recently bought AU$82k worth of stock Jun 14
No longer forecast to breakeven May 30
MD, CEO & Director recently bought AU$52k worth of stock Apr 22
MD, CEO & Director recently bought AU$54k worth of stock Mar 31
MD, CEO & Director recently bought AU$64k worth of stock Mar 08
First half 2023 earnings released: AU$0.01 loss per share (vs AU$0.006 loss in 1H 2022) Feb 25
ImpediMed Limited to Report Q2, 2023 Results on Jan 30, 2023 Jan 24
ImpediMed Limited Presents New Data at 2022 San Antonio Breast Cancer Symposium Shows Early Detection Using L-Dex and Intervention Improves Lymphedema Progression-Free Survival Dec 16 Impedimed Limited Announces CEO Changes
ImpediMed Limited Announces Management Changes Nov 22
Less than half of directors are independent Nov 17
Executive Director & Interim CEO recently bought AU$164k worth of stock Nov 01
Less than half of directors are independent Oct 29
ImpediMed Limited Announces Current Data Support Early Detection and Intervention to Reduce Rates of Breast Cancer Related Lymphedema Oct 27
ImpediMed Limited to Report Q1, 2023 Results on Oct 19, 2022 Oct 13
ImpediMed Expands Use of SOZO in Leading Cancer Centers Focused on Reducing the Impact of Lymphedema after Breast Cancer Oct 12
ImpediMed Announces U.S. Launch of Lymphedema Prevention Program with GenesisCare a Global Organization Dedicated to Care of Cancer Patients Oct 05
ImpediMed Limited Announces Board Changes Aug 30
Full year 2022 earnings released: AU$0.01 loss per share (vs AU$0.017 loss in FY 2021) Aug 30
ImpediMed Limited, Annual General Meeting, Oct 26, 2022 Aug 29
Less than half of directors are independent Jul 28
ImpediMed Limited Announces Executive Changes Jul 27 ImpediMed Limited Announces Resignation of Richard Carreon as Managing Director
ImpediMed Limited Announces Release of the New Version 4.1 Software for the SOZO Digital Health Platform Jun 02
No longer forecast to breakeven Apr 27
ImpediMed Limited to Report Q3, 2022 Results on Apr 28, 2022 Apr 22
New Bone Data Showing Strong Correlation Between ImpediMed's SOZO and DXA in Cancer Patients Presented At 39Th Annual Miami Breast Cancer Conference Mar 07
No longer forecast to breakeven Mar 05
First half 2022 earnings: EPS in line with expectations, revenues disappoint Mar 01
Now 22% undervalued Feb 15
Forecast to breakeven in 2024 Sep 23
FDA Grants Breakthrough Device Designation for ImpediMed's SOZO Digital Health Platform for Renal Failure Aug 31
Full year 2021 earnings released: AU$0.02 loss per share (vs AU$0.036 loss in FY 2020) Aug 26
Impedimed Announces Next Generation of Sozo® Digital Health Platform Software Jun 08
ImpediMed Limited Announces Official Release of SOZO Version 4.0 Software May 25
First half 2021 earnings released: AU$0.01 loss per share (vs AU$0.026 loss in 1H 2020) Feb 23
ImpediMed Limited to Report Q2, 2021 Results on Jan 28, 2021 Jan 21
ImpediMed Limited Announces PREVENT Trial Finishes - Final Patient Completes Follow-Up Jan 12 Impedimed Limited Announces the Publication of A New Study Demonstrating That the Company's Lymphedema Prevention Program
ImpediMed Limited Secures First Commercial Heart Failure Sales Nov 18
ImpediMed Limited Announces NSW Health Further Expands Lymphoedema Prevention Program Nov 16
AstraZeneca Selects SOZO for Second Large Renal Trial Nov 09
HFSA Poster Supports HF-Dex in the Management of HF Patients Oct 04
Impedimed Limited Announces Collaboration with the Live Today Foundation to Increase Awareness and Access to Care for Cancer Patients At Risk or Suffering from Lymphedema Oct 03
Impedimed Limited Announces Contract Valued at over AUD 2 Million for its SOZO Digital Health Platform to Be Used in Clinical Trial Being Conducted for AstraZeneca Sep 30
ImpediMed Limited(ASX:IPD) dropped from S&P/ASX Emerging Companies Index Sep 21
ImpediMed Limited Auditor Raises 'Going Concern' Doubt Sep 01
Earnings released Aug 26
ImpediMed Limited to Report Q4, 2020 Results on Jul 28, 2020 Jul 21
ImpediMed Limited announced that it has received AUD 0.227339 million in funding Jul 07 Rendement voor aandeelhouders IPD AU Medical Equipment AU Markt 7D 1.9% 3.8% 1.1% 1Y -61.4% 17.6% 18.3%
Bekijk het volledige aandeelhoudersrendement
Rendement versus industrie: IPD presteerde slechter dan de Australian Medical Equipment -sector, die het afgelopen jaar een rendement van 17.6 % opleverde.
Rendement versus markt: IPD presteerde slechter dan Australian Market , dat het afgelopen jaar een rendement van 18.3 % opleverde.
Prijsvolatiliteit Is IPD's price volatile compared to industry and market? IPD volatility IPD Average Weekly Movement 10.1% Medical Equipment Industry Average Movement 9.8% Market Average Movement 8.4% 10% most volatile stocks in AU Market 17.5% 10% least volatile stocks in AU Market 3.5%
Stabiele aandelenkoers: IPD heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 10% ) van IPD is het afgelopen jaar stabiel geweest.
Over het bedrijf ImpediMed Limited, een medisch technologiebedrijf, produceert en verkoopt medische apparatuur op basis van bio-impedantiespectroscopie (BIS) technologie in de Verenigde Staten en Europa. Het bedrijf biedt SOZO, een niet-invasief BIS-apparaat voor de klinische beoordeling van lymfoedeem en levert een momentopname van de vochtstatus en de weefselsamenstelling; L-Dex analyse voor lymfoedeem; BodyComp Analysis, een point-of-car lichaamssamenstellingsanalyse; en HF-Dex analyse voor point-of-care hartfalen vochtbeoordeling. Het bedrijf levert ook SFB7, een éénkanaals, tetrapolair BIS-apparaat voor het analyseren van de lichaamssamenstelling bij gezonde mensen; en ImpediVET, een éénkanaals, tetrapolair (BIS) apparaat dat de vochtstatus en de weefselsamenstelling meet voor veterinaire toepassingen.
Meer tonen ImpediMed Limited Samenvatting Hoe verhouden de winst en inkomsten van ImpediMed zich tot de beurswaarde? IPD fundamentele statistieken Marktkapitalisatie AU$111.30m Inkomsten(TTM ) -AU$19.79m Inkomsten(TTM ) AU$10.32m
10.8x P/S-verhouding
-5.6x Koers/Winstverhouding Inkomsten en omzet Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM) IPD resultatenrekening (TTM ) Inkomsten AU$10.32m Kosten van inkomsten AU$1.31m Brutowinst AU$9.01m Overige uitgaven AU$28.80m Inkomsten -AU$19.79m
Laatst gerapporteerde inkomsten
Jun 30, 2024
Volgende inkomensdatum
n.v.t.
Winst per aandeel (EPS) -0.0098 Brutomarge 87.27% Nettowinstmarge -191.78% Schuld/Eigen Vermogen Verhouding 0%
Hoe presteerde IPD op de lange termijn?
Bekijk historische prestaties en vergelijking
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
